Scarica l'app Stockscreener
91.69
1.27%
1.15
Dopo l'orario di chiusura:
91.69
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca PLC Borsa (AZN) Ultime notizie
AstraZeneca plc Stock Is Quietly Going Off — Is This Your Next Power Move? - AD HOC NEWS
Is This Dividend King Stock a Buy After a Major Development? - The Motley Fool
Migdal Insurance & Financial Holdings Ltd. Acquires Shares of 194,000 AstraZeneca PLC $AZN - MarketBeat
Prediction: Analysts think the AstraZeneca share price will do this in 2026 - MSN
Eyes on Asia: AirNexis, AstraZeneca, Syngene International - BioXconomy
Astrazeneca expands China cell therapy footprint with Abelzeta CAR T - BioWorld MedTech
AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates - TechStock²
AstraZeneca to delist from Nasdaq, join NYSE in February - Reuters
Why Is AstraZeneca Stock Trading Lower Today?AstraZeneca (NASDAQ:AZN) - Benzinga
AstraZeneca to move NYSE listing, withdraw from Nasdaq at end of January By Investing.com - Investing.com South Africa
AstraZeneca (AZN) Shifts Listing from Nasdaq to NYSE - GuruFocus
AstraZeneca to move NYSE listing, withdraw from Nasdaq at end of January - Investing.com
Dynasty Wealth Management LLC Invests $3.27 Million in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca to complete direct listing in NY on February 2 - marketscreener.com
AstraZeneca PLC (AZN) Gains After Successful Saphnelo Trial - Finviz
AstraZeneca PLC (NASDAQ:AZN) Emerges as a Quality Investment Candidate - Chartmill
AstraZeneca (AZN) to Consolidate Stock Listings on NYSE - GuruFocus
AstraZeneca To Move Nasdaq Listing To NYSE - DirectorsTalk Interviews
AstraZeneca Plans NYSE Listing for Shares, US Debt - Mirage News
AstraZeneca to complete direct listing of ordinary shares and all US debt securities on the New York Stock Exchange - AstraZeneca
AstraZeneca (AZN): EMA Considers Enhertu for Breast Cancer Treat - GuruFocus
AstraZeneca share price slips in London as tariff threat rattles markets; EMA review and earnings in focus - TechStock²
AstraZeneca's Subcutaneous Saphnelo Shows Significant Disease Reduction in Landmark Lupus Trial - Finviz
AstraZeneca’s Subcutaneous Saphnelo Shows Significant Disease Reduction in Landmark Lupus Trial - Yahoo Finance
AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy - Yahoo Finance
Prediction: analysts think the AstraZeneca share price will do this in 2026 - Yahoo Finance UK
AbelZeta and AstraZeneca Reach $630 Million Acquisition Agreement - Intellectia AI
AstraZeneca PLC (NASDAQ:AZN) Short Interest Update - MarketBeat
AstraZeneca PLC $AZN Shares Sold by QRG Capital Management Inc. - MarketBeat
AstraZeneca PLC $AZN Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
AstraZeneca PLC agreed to acquire remaining 50% stake in China rights to GPC3 armored CAR-T therapy from Abelzeta Inc. for $630 million. - marketscreener.com
Trend Review: Does AstraZeneca PLC Depositary Receipt have a sustainable dividendEarnings Miss & Weekly High Momentum Picks - baoquankhu1.vn
AstraZeneca share price steadies after Thursday drop as traders eye Nasdaq-100 reshuffle - TechStock²
Klein Pavlis & Peasley Financial Inc. Acquires New Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca’s Cell Therapy Manufacturing Facility, Maryland, USA - Pharmaceutical Technology
AstraZeneca (AZN) Weighs FDA Fast-Track Risks Amid Legal Concerns - GuruFocus
Deutsche Bank Maintains ASTRAZENECA PLC(AZNCF.US) With Sell Rating, Raises Target Price to $147.24 - Futubull
AZN Stock Price, Forecast & Analysis | ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) - Chartmill
AstraZeneca (AZN) Acquires Modella AI to Boost Cancer Research - GuruFocus
AstraZeneca Acquires Modella AI to Accelerate Cancer Therapy Development - Intellectia AI
JPMorgan Chase & Co. Reiterates Overweight Rating for AstraZeneca (LON:AZN) - MarketBeat
AstraZeneca (AZN) Involvement in Emergent's Legal Settlement - GuruFocus
What Makes AstraZeneca (AZN) a Strong Growing Company? - Insider Monkey
AstraZeneca Spotlights 2025 Growth, 2026 Launch Wave and $80B 2030 Goal at JPM Conference - Yahoo Finance
Rep. Julia Letlow Buys AstraZeneca PLC (NASDAQ:AZN) Shares - MarketBeat
AstraZeneca (NASDAQ:AZN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition - Pharmaceutical Technology
Manning & Napier Advisors LLC Sells 390,342 Shares of AstraZeneca PLC $AZN - MarketBeat
Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale - marketscreener.com
AstraZeneca (LON:AZN) Hits New 52-Week HighHere's Why - MarketBeat
Market Overview: Whats AstraZeneca PLC Depositary Receipts historical returnMarket Performance Recap & Intraday High Probability Alerts - baoquankhu1.vn
AstraZeneca: acquires Modella AI to strengthen its oncology research - marketscreener.com
AstraZeneca stock rating reiterated at Buy by Guggenheim ahead of Q4 results - Investing.com UK
AstraZeneca Buys US-based Modella AI - marketscreener.com
AstraZeneca CFO on M&A Strategy and Obesity Market - marketscreener.com
AstraZeneca to acquire Modella AI to speed oncology drug research - Reuters
AstraZeneca (AZN) Awaits Conclusion of US Pharma Import Probe - GuruFocus
Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company - marketscreener.com
AstraZeneca (AZN) Broadens Oncology Efforts with Acquisition of ModellaAI - GuruFocus
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):